ArticleEuropean journal of nuclear medicine and molecular imaging2018
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.PloS one · 2019Pooled it
- Trial
- Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.Journal of cancer research and clinical oncology · 2023Trial
- Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.Haematologica · 2022Trial
- High total metabolic tumor volume at baseline predicts survival independent of response to therapy.Blood · 2020Trial
- Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis.Current oncology (Toronto, Ont.) · 2026Article
- Metabolic Bulk Volume is an independent prognostic factor and facilitates identifying high risk cases for DLBCL patients treated with the R-CHOP.Frontiers in oncology · 2026Article
- Role ofTranslational cancer research · 2025Article
- Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response.Haematologica · 2025Article
- Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials.European journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic Value of Multiple Manual Segmentation Methods for Diffuse Large B-Cell Lymphoma withCurrent oncology (Toronto, Ont.) · 2025Article
- Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model.EJNMMI research · 2024Article
- Article
- Prognostic relevance of tumor-infiltrating CD4Haematologica · 2024Article
- Semi-supervised learning towards automated segmentation of PET images with limited annotations: application to lymphoma patients.Physical and engineering sciences in medicine · 2024Article
- Metabolic tumour area: a novel prognostic indicator based onBMC cancer · 2024Article
- TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images - a multi-center generalizability analysis.European journal of nuclear medicine and molecular imaging · 2024Article
- Baseline and interimFrontiers in oncology · 2024Article
- Prediction nomogram based on 18F-FDG PET/CT and clinical parameters for patients with diffuse large B-cell lymphoma.Annals of hematology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the predictive significance of total metabolic tumour volume (TMTV) measured on baseline FDG PET/CT and its value in addition to gene expression profiling using a new method of gene analysis (rapid reverse transcriptase multiplex ligation-dependent probe amplification assay, RT-MLPA) in patients with diffuse large B-cell lymphoma treated with R-CHOP or R-CHOP-like chemotherapies.
methodsThe analysis included 114 patients. TMTV was measured using a 41% SUVmax threshold and tumours were classified into GCB or ABC subtypes according to the RT-MLPA assay.
resultsThe median follow-up was 40 months. the 5-year progression-free survival (PFS) was 54% and the 5-year overall survival (OS) was 62%. The optimal TMTV cut-off value was 261 cm
conclusionsThis integrated risk model could lead to more accurate selection of patients that would allow better individualization of therapy.
Indexed as
Identifiers
29344718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.